Last reviewed · How we verify
Shigella 4V
At a glance
| Generic name | Shigella 4V |
|---|---|
| Sponsor | LimmaTech Biologics AG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shigella 4V CI brief — competitive landscape report
- Shigella 4V updates RSS · CI watch RSS
- LimmaTech Biologics AG portfolio CI